Determinants of amikacin first peak concentration in critically ill patients
Clicks: 327
ID: 269429
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
70.2
/100
327 views
216 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #1 of 2 articles by views in fundamental & clinical pharmacology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Amikacin antimicrobial effect has been correlated with the ratio of the peak concentration (Cmax ) to the minimum inhibitory concentration. A target Cmax ≥ 60-80 mg/L has been suggested. It has been shown that such target is not achieved in a large proportion of critically ill …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (45 words).
Try re-searching for a better abstract.
| Reference Key |
c2018fundamentaldeterminants
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Boidin C;Jenck S;Bourguignon L;Torkmani S;Roussey-Jean A;Ledochowski S;Marry L;Ammenouche N;Dupont H;Marçon F;Allaouchiche B;Bohé J;Lepape A;Goutelle S;Friggeri A;; |
| Journal | fundamental & clinical pharmacology |
| Year | 2018 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
female
male
middle aged
regression analysis
Retrospective Studies
microbial sensitivity tests
intensive care units
anti-bacterial agents / therapeutic use*
critical illness
amikacin / therapeutic use*
pmid:29660162
doi:10.1111/fcp.12374
clément boidin
sophie jenck
arnaud friggeri
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.